| Status: In progress | |
For the off-label treatment of locally advanced treatment-naive stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer. |
|
Medicine details |
|
| Medicine name | dostarlimab (Jemperli®) |
| Formulation | 500 mg concentrate for solution for infusion |
| Reference number | OW26 |
| Indication | As above |
| Company | GlaxoSmithKline UK |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | One Wales |
| Status | In progress |
| AWMSG meeting date | 11/07/2023 |
| Date of issue | TBA |